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Abstract: In May 2015, the hypoxia research community came together at the largest meeting 
in this field to date, to present and discuss their most recent and mainly unpublished findings. 
This meeting report aims to summarize the data presented at this conference, which were broadly 
separated into the areas of the cellular hypoxic response, the relevance of the hypoxic response in 
health and disease, and the development of new therapeutics targeting the hypoxic response.
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Introduction
The Keystone Symposium “Hypoxia: From Basic Mechanisms to Therapeutics” 
was held in Dublin, Ireland, from May 12th–17th, 2015 in conjunction with the 
European HypoxiaNet meeting. The meeting was organized by four internationally 
highly regarded experts from the hypoxia field: Dr Cormac T Taylor (University 
College Dublin, Dublin, Ireland), Dr M Celeste Simon (The Howard Hughes Medi-
cal Institute (HHMI)/University of Pennsylvania, Philadelphia, PA, USA), Dr Sean P 
Colgan (University of Colorado Denver, Denver, CO, USA), and Dr Roland H Wenger 
(University of Zürich, Zürich, Switzerland).
HypoxiaNet (http://www.hypoxianet.com) is a network of over 600 European 
researchers in the hypoxia field from 28 different countries that was established by 
Dr Roland H Wenger and Dr Dörthe M Katschinski (University of Göttingen, Göttingen, 
Germany) in 2009. The initial funding for HypoxiaNet was provided by the European 
Cooperation in Science and Technology (COST) Action program of the EU, and this 
joint symposium was the 11th HypoxiaNet meeting to be held since 2009.
This conference was also the seventh Keystone meeting in the hypoxia research 
field and the first occasion on which it was held outside of North America.1 It was a 
huge success, with almost 500 participants from 36 different countries including over 
200 PhD students and postdoctoral fellows, making it the largest gathering of hypoxia-
focused researchers that has taken place to date.
Hypoxia, or a decreased oxygen supply over demand, plays a major role in health and 
disease.2–6 Changes in whole-body oxygen supply are sensed in the carotid body and in 
the kidney, leading to the adaptation of alveolar ventilation and of erythropoietin (Epo) 
synthesis, respectively.7 On the cellular level, decreased oxygen availability is sensed 
ubiquitously by four different oxygen-sensing hydroxylases (prolyl hydroxylase domains 
[PHDs] 1–3 and factor-inhibiting hypoxia-inducible factor [HIF] [FIH]). The hydroxy-
lases were discovered as regulators of HIF, the master transcription factor for cellular 
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adaptation to hypoxic conditions.8–12,15 Hypoxia-sensitive 
signaling pathways play a major role in disease, ranging from 
anemia and cancer to chronic inflammation.13,14 Many phar-
maceutical companies are currently developing inhibitors of 
the oxygen-sensing enzymes, with compounds now in clini-
cal phase IIb and phase III trials.16 All these aspects, as well 
as HIF-independent aspects of the hypoxic response, were 
presented and discussed during the Keystone and HypoxiaNet 
Symposium.
The meeting commenced with a keynote address by Dr Peter 
F Carmeliet (University of Leuven, VIB Vesalius Research Cen-
tre, Leuven, Flanders, Belgium), who highlighted the impor-
tant and diverse roles of oxygen sensing in spine formation, 
metastasis, and neuroprotection. Furthermore, he described the 
importance of endothelial cell metabolism in angiogenesis.
During several sessions, distinguished scientists presented 
their latest (and mostly unpublished) data from research in the 
hypoxia field. In addition, each session contained short talks 
that gave young investigators the opportunity to present their 
data to the wider hypoxia research community. Due to the 
size of the conference and the diversity of the field, it was 
not possible to provide a comprehensive summary of all 
topics discussed at the meeting in this short meeting report. 
We focused instead on giving an overview of the meeting 
to highlight the current interests and focus of the field, with 
some examples in each case. The topics discussed at this 
meeting have been broadly separated into the following three 
sections: 1) “Unraveling the cellular hypoxic response”, 
2) “Relevance and impact of the hypoxic response in health 
and disease”, and 3) “Developing new therapeutics targeting 
the hypoxic response”.
Unraveling the cellular hypoxic 
response
The discovery of HIF was the first major step toward the 
unraveling of the cellular hypoxic response.17 This discovery 
was followed by the description of the cellular oxygen sen-
sors PHDs 1–3 and FIH8–12,15 a decade later. Since then, the 
cellular hypoxic response has been extensively studied, with 
the major focus on the HIF transcription factor and on the 
oxygen-sensing hydroxylases. Three major areas about the 
cellular hypoxic response were discussed at the Keystone 
and HypoxiaNet Symposium.
the search for novel cellular oxygen 
sensors
The HIF hydroxylases belong to the Fe(II)- and 2-oxoglutarate-
dependent dioxygenase superfamily, which consists of 
approximately 70 different proteins. Therefore, it seems 
likely that other 2-oxoglutarate-dependent oxygen sensors 
are present in cells. Also, existence of proteins with oxygen 
sensing capability from other protein families cannot be 
excluded. However, to date no further oxygen sensor has 
been described at the level of detail that PHDs 1–3 and FIH 
have been described at. Interestingly, Dr Peter J Ratcliffe 
(University of Oxford, Oxford, UK) presented data describing 
a possible new oxygen-sensing enzyme, which is surprisingly 
a monooxygenase and may be involved in oxygen-dependent 
neuropeptide processing and modification.
Hydroxylase targets outside the HIF 
pathway 
To date, only few proteins outside the HIF pathway have 
been found to be regulated by proline hydroxylation.18–21 
FIH-dependent asparagine hydroxylation has been 
described for several proteins containing ankyrin-repeat 
domains, such as ASPP2, IκBα, notch-1, and tankyrase.22–25 
However, the functional impact of asparagine hydroxyla-
tion outside the HIF pathway is less clear. Dr Daniel J Peet 
(University of Adelaide, Adelaide, SA, Australia) presented 
results demonstrating that FIH-dependent asparagine 
hydroxylation of the ion channel transient receptor potential 
vanilloid 3 leads to the oxygen-dependent regulation of its 
activity. Dr Cormac T Taylor demonstrated that a specific 
deubiquitinating enzyme may be a new FIH target protein 
and that FIH-dependent asparagine hydroxylation of this 
deubiquitinase may result in changes in cellular energy 
metabolism. This could give a first mechanistic insight 
into the previously reported metabolic phenotype of FIH 
knockout mice.26 Dr Dörthe M Katschinski discussed her 
data showing that hypoxia leads to increased clathrin- and 
caveolin-independent endocytosis and to changes between 
the cis and trans Golgi network. This regulation seemed to 
be independent of HIF as well.
Novel regulatory mechanisms of the HIF 
transcription factor
It has been demonstrated that HIF-1α is not only regu-
lated by the hydroxylases but is also regulated by sev-
eral other mechanisms.27 For example, activation of the 
NF-κB pathway can lead to an upregulation of the HIF-1α 
protein through enhanced transcription of the HIF1A 
gene.28–30 Another example is the regulation of HIF-1α 
by the microRNA miR-155, which serves as a negative 
feedback loop in response to hypoxia.31 Dr Edurne Berra 
(Center for Cooperative Research in Biosciences [CIC 
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bioGUNE], Biscay, Spain) highlighted a role for deubiq-
uitinating enzymes in the regulation of HIF-1α protein 
levels and discussed a specific deubiquitinase as a newly 
discovered regulator of HIF-1α. Dr Thomas Kietzmann 
(University of Oulu, Oulu, Finland) presented data about 
a novel regulation of HIF-1α by an E3 ubiquitin ligase 
in conjunction with a specific deubiquitinase. Dr Paul 
N Moynagh (National University of Ireland, Maynooth, 
Ireland) discussed a novel impact of a further specific E3 
ubiquitin ligase on HIF-1α regulating IL-1β expression. 
Overall, these presentations illustrate that the interaction 
of the HIF pathway and the ubiquitin system is a current 
and rapidly developing focus of the field.
Relevance and impact of the 
hypoxic response in health  
and disease
Reduced oxygen availability leads to intrinsic physiologic 
responses at both cellular and systemic levels. Our ability 
to respond to a decrease in oxygen availability is imperative 
for adaptation and survival. Hypoxia is associated with most 
diseases both acute and chronic.32 Not surprisingly, patho-
logic conditions can result in altered/impaired physiologic 
responses to hypoxia.33 Unraveling the complex nature of 
oxygen sensing in health and disease states is essential for 
further understanding of disease processes as well as the 
identification of potential therapeutic targets. Three particu-
lar areas of interest were highlighted at the Keystone and 
HypoxiaNet Symposium.
physiological oxygen sensing by the 
kidney
Discrepancy in findings identifying Epo-producing cells in 
the kidney has led historically to debate over the exact identity 
and location of these cells, although recent results point to 
renal cortical interstitial cells. In addition, the detailed cel-
lular oxygen sensing mechanisms of the Epo-producing cells 
of the kidney remain to be fully elucidated due to the absence 
of a cell culture system of renal Epo-producing cells.34 
Dr Roland H Wenger and Dr Volker H Haase (Vanderbilt 
University, Nashville, TN, USA) presented different mouse 
models designed for the investigation of these cells in vivo 
and discussed possibilities for future research in order to 
further elucidate oxygen sensing mechanisms in the kidney. 
Dr Josef Prchal (University of Utah, Salt Lake City, UT, 
USA) discussed a link between renal oxygen sensing and 
the adaptation of the Tibetan population to high altitude by 
presenting mutations in the hypoxia-sensing pathways that 
were discovered in the Tibetan population and that lead to 
polycythemia.
Mechanisms of oxygen sensing by the 
carotid body
The carotid body plays an essential role in the physiologic 
response to reduced oxygen availability by adapting alveolar 
ventilation.35 However, the exact molecular mechanism(s) of 
oxygen sensing in the carotid body remain(s) to be elucidat-
ed.36 Dr José López-Barneo (Hospital Universitario Virgen 
del Rocío, Seville, Spain) argued that reactive oxygen spe-
cies are important intracellular messengers for sensing of 
low oxygen concentrations, while Dr Nanduri R Prabhakar 
(University of Chicago, Chicago, IL, USA) discussed H
2
S, 
CO, and NO as relevant gaseous messengers.
the hypoxic response in cancer
The impact of the hypoxic response in the complex setting 
of tumorigenesis is a key area of interest.37 Hypoxia is in 
many tumors a negative prognostic and predictive factor 
due to its impact on a broad range of cellular and physi-
ological/pathophysiological responses including angiogen-
esis, vasculogenesis, invasiveness, metastasis, metabolism, 
cell death resistance, genomic instability, and chemo- and 
radioresistance.38 The role of the oxygen-sensing pathway 
in cancer is likely to be highly context- dependent.39,40 At 
the Keystone and HypoxiaNet Symposium, Dr Till Acker 
(University of Giessen, Giessen, Germany) focused on the 
role of PHD 3 in cancer and demonstrated that loss of PHD 3 
promotes tumor growth and impacts on therapy response. Dr 
Gregg L Semenza (John Hopkins University School of Medi-
cine, Baltimore, MD, USA) discussed the role of HIF-1α 
and the transcriptional co-activator with PDZ-binding motif 
(TAZ) in the breast cancer stem cell phenotype and their 
impact on breast cancer stem cell enrichment. In clear-cell 
renal cell carcinoma, HIF-2α was found to promote tumor 
cell viability through regulation of lipid storage, as presented 
by Dr M Celeste Simon.
Developing new therapeutics 
targeting the hypoxic response
The development of pharmaceutical drugs targeting the HIF 
pathway is a highly dynamic, rapidly growing, and promising 
field. To date, 12 different companies are known to have devel-
oped inhibitors targeting the oxygen-sensing hydroxylases: 
FibroGen, Bayer Pharma AG, GlaxoSmithKline, Akebia 
Therapeutics, Amgen, Merck & Co, Inc., Janssen, Akros 
Pharma Inc., Procter and Gamble, Daiichi Sankyo Inc., Crys-
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tal Genomics, and Kowa.16,41 In addition, Astellas Pharma 
and AstraZeneca collaborate with FibroGen.16 At the begin-
ning of this year 26 different clinical trials with hydroxylase 
 inhibitors were registered with http://www.ClinicalTrials.
gov.16 Current clinical trials and emerging therapeutic options 
for hydroxylase inhibitors were discussed at this meeting.
Development of hydroxylase inhibitors 
for treatment of anemia
Several different hydroxylase inhibitors are currently inves-
tigated in clinical trials for their efficacy in the treatment of 
anaemia in chronic kidney disease. The pharmaceutical com-
panies FibroGen, GlaxoSmithKline, and Bayer Pharma AG 
presented their most recent advances in clinical trials at this 
meeting. Importantly, Phase III clinical trials are currently 
starting for the FibroGen compound FG-4592 (ASP1517, 
Roxadustat). The different compounds in several clinical 
trial phases have recently been reviewed.16
emerging treatment options for 
hydroxylase inhibitors
To date, one highly promising effect of hydroxylase inhibitor 
treatment, in addition to anemia, has been shown in murine 
models of inflammatory bowel disease (IBD).42 The num-
ber of diseases described for which hydroxylase inhibitors 
might be a potential treatment option is rapidly expanding. 
Dr Martin Schneider (University of Heidelberg, Heidelberg, 
Germany) presented data demonstrating that pharmacologic 
hydroxylase inhibition leads to enhanced liver regeneration 
following hepatectomy, which could be beneficial in diseases 
such as colon cancer, where metastases are often found in the 
liver, leading to the resection of large portions of the organ.43 
Dr Sean P Colgan, Dr Yatrik Shah (University of Michigan, 
Ann Arbor, MI, USA), and Dr Eric L Campbell (University 
of Colorado, Anschutz Medical Campus, Aurora, CO, USA) 
made a critical point about the importance of HIF-1α and 
HIF-2α stabilization in IBD, highlighting the potential of 
targeting the hydroxylases pharmacologically for treatment 
of IBD. Interestingly, a new delivery mechanism for drugs 
(including hydroxylase inhibitors) allowing low-dose target-
ing of specific areas of the gut for treatment of diseases such 
as IBD was reported by the company Sigmoid Pharma.
Dr Luke AJ O’Neill (Trinity College Dublin, Dublin, 
Ireland) presented findings that metabolic reprogramming 
of macrophages is an important factor in immunity and that 
HIF-1α plays a critical role in these regulations. Furthermore, 
he showed that pharmacologic interference with these pro-
cesses can be anti-inflammatory. Overall, several speakers 
at this meeting highlighted the anti-inflammatory action of 
hydroxylase inhibitors and showed the great potential and 
interest in this mode of action of these drugs.
The importance of oxygen sensing and missing links in 
the current knowledge of oxygen sensing were highlighted 
by the keynote speaker, Dr Salvador Moncada (University 
of Manchester, Manchester, UK). He presented a retrospec-
tive of his work, indicating that oxygen and NO interact at 
the level of the cytochrome oxidase complex IV and that 
NO might regulate oxygen consumption. He emphasized 
that this important question needs future studies to further 
elucidate the interaction between oxygen and NO in oxygen 
sensing.
Concluding remarks
In addition to the oral presentations overviewed in the pres-
ent short report, there were over 300 posters presented at the 
Keystone and HypoxiaNet Symposium, which reflected the 
scale of hypoxia research and represented the broad range 
of interests within the field. Overall, the symposium allowed 
the attendees to disseminate new scientific knowledge, to 
discuss new methodologies, and to form new collaborations. 
In addition, it also facilitated interaction between clinicians 
and academic and industrial researchers, and was a major 
educational platform for junior researchers in the field. The 
next Keystone Symposium of the hypoxia research field 
will be held in 2017, with Dr M Celeste Simon as lead 
organizer. The 2015 symposium ended as any important 
and intriguing meeting should, with an anthem written and 
performed by Dr Cormac T Taylor about the field of and the 
dedication to hypoxia research: https://www.youtube.com/
watch?v=nD8gzUOYnfE and https://www.youtube.com/
watch?v=RrFe4mEWeNU.
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